nach oben

Journal of Neurology

Erschienen in:

01.05.2015 | Review

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

verfasst von: Raffaele Iorio, Valentina Damato, Paolo Emilio Alboini, Amelia Evoli

Erschienen in: Journal of Neurology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused by circulating antibodies specif ic for the post-synaptic acetylcholine receptor or, in a minority of cases, for the muscle-specific tyrosine-kinase and the low-density lipoprotein receptor-related protein 4. A wide range of symptomatic and immunosuppressive treatments is currently available for MG patients with variable outcome. However, most immunosuppressive treatments are characterized by delayed onset of action and in some cases are not sufficient to induce stable remission of the disease. Rituximab (RTX) is a chimaeric monoclonal antibody specific for the CD20 B-cell surface antigen. Recent studies have provided evidence that RTX may be an effective treatment for patients with myasthenia gravis (MG) who are refractory to standardized immunosuppressive therapy. We performed a systematic review and a meta-analysis of the efficacy and safety of RTX in myasthenia gravis considering the potential predictive factors related to patients’ response to RTX in this disease.

Meriggioli MN, Sanders DB (2012) Muscle antibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8:427–438PubMedCentralCrossRefPubMed

Verschuuren JJ, Huijbers MG, Plomp JJ et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918–923CrossRefPubMed

Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902CrossRefPubMed

Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA (2008) Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 1132:305–314PubMedCentralCrossRefPubMed

Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMed

Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9:10–25CrossRefPubMed

Iorio R, Pittock SJ (2014) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. Clin Exp Neuroimmunol 5:175–187CrossRef

Iorio R, Assenza G, Tombini M, Colicchio G, Della Marca G, Benvenga A, Damato V, Rossini PM, Vollono C, Plantone D, Marti A, Batocchi AP, Evoli A (2014) The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy. Eur J Neurol. doi:10.1111/ene.12529 PubMed

Zaja F, Russo D, Fuga G, Perella G, Baccarani M (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55:1062–1063CrossRefPubMed

10.

Wylam M, Anderson P, Kuntz NL, Rodriguez V (2003) Successful treatment of refractory myasthenia gravis using Rituxomab: a pediatric case report. J Pediatr 143:674–677CrossRefPubMed

11.

Gajra A, Vajpayee N, Grethlein SJ (2004) Response of myasthenia gravis to rituximab in a patient with non-hodgkin lymphoma. Am J Hematol 77:196–197CrossRefPubMed

12.

Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda A (2005) Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 84:548–550CrossRefPubMed

13.

Lin PT, Martin BA, Weinacker AB, So YT (2006) High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 33:433–435CrossRefPubMed

14.

Hain B, Jordan K, Deschauer M, Zierz S (2006) Successful treatment of Musk-antibody positive myasthenia gravis with Rituximab. Muscle Nerve 33:575–580CrossRefPubMed

15.

Thakre M, Inshasi J, Marashi M (2007) Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254:968–969CrossRefPubMed

16.

Chan A, Lee DH, Linker R, Mohr A, Toyka KV, Gold R (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254(11):1604–1606CrossRefPubMed

17.

Baek WS, Bashey A, Sheean GL (2007) Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 78:771PubMedCentralCrossRefPubMed

18.

Kerkeni S, Marotte H, Miossec P (2008) Improvement with Rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 38:1343–1345CrossRefPubMed

19.

StroberJ MD, Cowan MJ, Horn BN (2009) Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 66:659–661

20.

Stieglbauer K, Topakian R, Schäffer V, Aichner FT (2009) Rituximab for myasthenia gravis. Three case reports and review of the literature. J Neurol Sci 280:120–122CrossRefPubMed

21.

Tzaribachev N, Schedel J, Koetter I, Kuemmerle-Deschner JB (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609PubMedCentralCrossRefPubMed

22.

Masroujeh R, Otrock ZK, Yamout B, Jabbour MN, Bazarbachi A (2010) Myasthenia gravis developing in a patient with CNS lymphoma. Int J Hematol 91:522–524CrossRefPubMed

23.

Sadnicka A, Reill MM, Mummery C, Brandner S, Hirsch N, Lunn MP (2011) Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 82:230–232CrossRefPubMed

24.

Lau AYL, Chan AYY, Mok VCT (2011) Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody–positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Hong Kong Med J 17:77–79PubMed

25.

Kuntzer T, Carota A, Novy J, Cavassini M, Du Pasquier RA (2011) Rituximab is successful in an HIV-positive patient with Musk myasthenia gravis. Neurology 76:757–758CrossRefPubMed

26.

Koul R, Al Futaisi A, Abdwani R (2012) Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 47:209–212CrossRefPubMed

27.

Jakubikova M, Pitha J, Latta J, Ehler E, Schutzner J (2013) Myasthenia gravis, Castleman disease, pemphigus and anti-phospholipid syndrome. Muscle Nerve 47:447–451CrossRefPubMed

28.

Renard D, Cornillet L, Castelnovo G (2013) Myocardial infarction after rituximab infusion. Neuromuscul Disord 23:599–601CrossRefPubMed

29.

Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48:992–993PubMedCentralCrossRefPubMed

30.

Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi FD (2014) Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 49:487–494CrossRefPubMed

31.

Jaretzki A, Barohn RB, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16–23CrossRefPubMed

32.

Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150CrossRefPubMed

33.

Leandro MJ, Becerra-Fernandez E (2011) B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:535–548CrossRefPubMed

34.

Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, Marqués AO, Rúa-Figueroa I, Fernández-Nebro A, Cáliz RC, López Longo FJ, Muñoz-Fernández S (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum (Epub ahead of print)

35.

Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54(2):613–620CrossRefPubMed

36.

Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66–73CrossRefPubMed

37.

Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A (2013) Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260:2163–2165CrossRefPubMed

38.

Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801–803CrossRefPubMed

39.

Hultin LE, Hausner MA, Hultin PM, Giorgi JV (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14:196–204CrossRefPubMed

40.

Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 107:4658–4663PubMedCentralCrossRefPubMed

41.

Winter O, Dame C, Jundt F, Hiepe F (2012) Pathogenic long-lived plasma cells their survival niches in autoimmunity, malignancy, and allergy. J Immunol 189:5105–5111CrossRefPubMed

42.

Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189–193CrossRefPubMed

43.

HERMES Trial Group, Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688CrossRef

44.

Mahévas M, Michel M, Weill JC, Reynaud CA (2013) Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol 4:494PubMedCentralCrossRefPubMed

Titel: Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
verfasst von: Raffaele Iorio
Valentina Damato
Paolo Emilio Alboini
Amelia Evoli
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 5/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7532-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Ocular motor measures of cognitive dysfunction in multiple sclerosis I: inhibitory control

Pitfalls in ataxia with ocular motor apraxia type 1: pseudodominant inheritance and very late onset

NEFL E396K mutation is associated with a novel dominant intermediate Charcot–Marie–Tooth disease phenotype

Respiratory dysfunction in Charcot–Marie–Tooth disease type 1A

Sporadic infantile-onset spinocerebellar ataxia caused by missense mutations of the inositol 1,4,5-triphosphate receptor type 1 gene